Search - tctmd.com

Displaying 21 - 40 of 60

Sort: Relevancy | Date

News Daily News

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

L.A. McKeown

January 13, 2023

News Opinion Editor's Corner

The Biggest News of 2022: TCTMD’s Top 10

Shelley Wood

December 30, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Conference News AHA 2022

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

Todd Neale

November 06, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2022

Shelley Wood

June 01, 2022

News Daily News

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

L.A. McKeown

May 05, 2022

News Daily News

FDA Approves Empagliflozin for Treatment of HFpEF

Michael O'Riordan

February 24, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Caitlin E. Cox

January 10, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Daily News

TCTMD’s Top 10 Most Popular Stories for September 2021

Shelley Wood

October 01, 2021

News Conference News HFSA 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Todd Neale

September 13, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Daily News

FDA Approves Dapagliflozin for CKD Patients

Michael O'Riordan

May 03, 2021

News Daily News

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Shelley Wood

December 17, 2020

Advertisement

HFrEF’s Financial Burden May Get Relief From Inflation Reduction Act

The Biggest News of 2022: TCTMD’s Top 10

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD

What’s Going to Be Hot at ESC 2022?

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

TCTMD’s Top 10 Most Popular Stories for May 2022

DELIVER Trial Scores a Win for Dapagliflozin in HFpEF

FDA Approves Empagliflozin for Treatment of HFpEF

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

As US Diabetes Rates Soar, AHA Urges CV Risk Factor Control

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Canagliflozin Improves Quality of Life in HF Patients

TCTMD’s Top 10 Most Popular Stories for September 2021

PRESERVED-HF: Dapagliflozin Improves Symptoms, Physical Limitations in HFpEF

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

FDA Approves Dapagliflozin for CKD Patients

AHA’s 2020 Top 10: ISCHEMIA, HCM, Early A-fib Intervention, and More

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content